Abstract
The European Society for Blood and Marrow Transplantation (EBMT), established in 1974, is the leading scientific society for professionals involved in haematopoietic stem-cell transplantation (HSCT).
The 2016 EBMT Annual Meeting, held in Valencia, Spain, brought together over 4,500 scientists, physicians, nurses, biologists, pharmacists, technicians and patients to discuss scientific data across a wide range of topics. New for this year was the 1st EBMT Pharmacists’ Day, viewing therapies from the pharmacist’s perspective, with the objective of achieving maximum clinical benefit. Here, and across the entire meeting, a major focus was invasive fungal infections (IFI). Despite the availability of three classes of antifungals (AFs) to treat IFI (including polyenes, azoles and echinocandins), mortality in haemato-oncology patients remains unacceptably high. Across the EBMT 2016 sessions, key opinion leaders highlighted the urgent need to improve management of IFI, and the bioavailability (BA) of azoles. Current strategies include the new tablet formulation of posaconazole, administered once a day (o.d.) without food; the extended half-life of the new prodrug isavuconazole; use of combination therapy; and personalized therapy such as dosing voriconazole according to CYP2C19 genotype. Looking to the future experimental strategies, including developing agents that destroy the biofilm which prevents AFs from reaching intracellular targets and loading neutrophils with azoles, were presented.Keywords: Antifungal, aspergillosis, EBMT, invasive fungal infections, mortality, posaconazole.
Graphical Abstract
Related Journals
Current Medicinal Chemistry
Current Pharmaceutical Design
Current Topics in Medicinal Chemistry
Current Respiratory Medicine Reviews
Infectious Disorders - Drug Targets
Endocrine, Metabolic & Immune Disorders - Drug Targets
Current HIV Research
Coronaviruses
Recent Advances in Inflammation & Allergy Drug Discovery
Current Probiotics
Related Books
Frontiers in Clinical Drug Research: Anti-Infectives
Frontiers in Anti-Infective Drug Discovery
Coronaviruses
Moving From COVID-19 Mathematical Models to Vaccine Design: Theory, Practice and Experiences
COVID-19: Effects in Comorbidities and Special Populations
An Update on SARS-CoV-2: Damage-response Framework, Potential Therapeutic Avenues and the Impact of Nanotechnology on COVID-19 Therapy
Mitochondrial DNA and the Immuno-inflammatory Response: New Frontiers to Control Specific Microbial Diseases
An Epidemiological Update on COVID -19
Frontiers in Clinical Drug Research – Anti Allergy Agents
Frontiers in Clinical Drug Research: Anti-Infectives
45
4
1
1